Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMatas, Jessica
dc.contributor.authorLlorenç, Victor
dc.contributor.authorFonollosa, Alex
dc.contributor.authorEsquinas López, Cristina
dc.contributor.authorDiaz-Valle, David
dc.contributor.authorBerasategui, Barbara
dc.date.accessioned2019-03-01T11:15:10Z
dc.date.available2019-03-01T11:15:10Z
dc.date.issued2019-01-24
dc.identifier.citationMatas J, Llorenç V, Fonollosa A, Esquinas C, Diaz-Valle D, Berasategui B, et al. Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis. PLoS One. 2019;14(1):e0210799.
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11351/3822
dc.descriptionPredictors; Macular edema; Non-infectious uveitis
dc.description.abstractAIMS: We aimed to investigate predictive factors for visual and anatomic outcomes in patients with macular edema secondary to non-infectious uveitis. MATERIAL AND METHODS: We conducted a multicenter, prospective, observational, 12-month follow-up study. Participants included in the study were adults with non-infectious uveitic macular edema (UME), defined as central subfoveal thickness (CST) of >300 μm as measured by spectral domain optical coherence tomography (SD-OCT) and fluid in the macula. Demographic, clinical and tomographic data was recorded at baseline, 1, 3, 6 and 12 months. Foveal-centered SD-OCT exploration was set as the gold-standard determination of UME using a standard Macular Cube 512x128 A-scan, within a 6 x 6 mm2 area, and the Enhanced High Definition Single-Line Raster. To assess favorable prognosis, the main outcomes analyzed were the best-corrected visual acuity (BCVA) and the CST. Favorable prognosis was defined as sustained improvement of BCVA (2 lines of gain of the Snellen scale) and CST (decrease of 20% of the initial value or <300 μm) within a 12 month period. RESULTS: Fifty-six eyes were analyzed. The number of eyes with sustained improvement in the CST was 48 (86.2%), against 23 (41.1%) eyes with sustained improvement in BCVA. Favorable prognosis, as defined above, was observed in 18 (32.1%) eyes. UME prognosis was negatively correlated with baseline foveal thickening, alteration in the vitreo-macular interface and cystoid macular edema. In contrast, bilaterally, systemic disease and the presence of anterior chamber cells were predictive of favorable prognosis. CONCLUSION: Available treatment modalities in UME may avoid chronic UME and improve anatomic outcome. However, the proportion of functional amelioration observed during 12 months of follow-up is lower. Thicker CST, alteration in the vitreo-macular interface and cystoid macular edema may denote less favorable prognosis. Conversely, bilaterally, systemic disease and anterior chamber cells may be associated with favorable prognosis in UME.
dc.language.isoeng
dc.publisherPublic Library of Science
dc.relation.ispartofseriesPLoS ONE;14(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectUveïtis
dc.subjectEdema - Tractament - Estudi de casos
dc.subject.meshMacular Edema
dc.subject.meshUveitis
dc.subject.mesh/drug therapy
dc.subject.meshCohort Studies
dc.titlePredictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1371/journal.pone.0210799
dc.subject.decsedema macular
dc.subject.decsuveítis
dc.subject.decs/tratamiento farmacológico
dc.subject.decsestudios de cohortes
dc.relation.publishversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210799
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Matas J, Llorenç V] Clinic Institute of Ophthalmology (ICOF), Hospital Clinic of Barcelona, Barcelona, Spain. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Fonollosa A] Department of Ophthalmology, BioCruces Health Research Institute, Hospital Cruces, University of the Basque Country, Baracaldo, Spain. [Esquinas C] Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Diaz-Valle D] Ophthalmology Department and Health Research Institute (IdISSC), Hospital Clinic of San Carlos, Madrid, Spain. [Berasategui B] Department of Ophthalmology, BioCruces Health Research Institute, Hospital Cruces, University of the Basque Country, Baracaldo, Spain.
dc.identifier.pmid30677041
dc.identifier.wosWOS:000456700400026
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record